对乙酰氨基酚作为重症和中度重症恶性疟患者的肾脏保护辅助治疗:一项随机、对照、开放标签试验
在孟加拉国两家医院开展的2期开放标签随机对照试验纳入62例重症恶性疟发热患者,比较对乙酰氨基酚(1g每6小时共72小时)联合静脉青蒿琥酯与单用青蒿琥酯。对乙酰氨基酚组72小时肌酐下降23%,对照组下降14%(P=.043);血红蛋白≥45000 ng/mL亚组分别为37%和14%(P=.010);对照组进展性肾损伤比例更高(亚分布风险比3.0,95%CI 1.1-8.5,P=.034)。
要点
- 对乙酰氨基酚组72小时肌酐下降23%,对照组下降14%,差异有统计学意义(P=.043)。
- 血红蛋白≥45000 ng/mL患者中对乙酰氨基酚组肌酐下降37%,对照组下降14%(P=.010)。
- 对照组进展性肾损伤比例更高(亚分布风险比3.0,95%CI 1.1-8.5,P=.034)。
核心结论
- 在这项原理验证研究中,对乙酰氨基酚在重症恶性疟患者中显示出肾脏保护作用且无安全性担忧证据,尤其是在有明显血管内溶血的患者中。
研究设计与样本
- 2期、开放标签、随机对照试验,在孟加拉国两家医院开展,纳入年龄>12岁的重症恶性疟发热患者62例,随机分为对乙酰氨基酚组(n=31)和不对乙酰氨基酚组(n=31),两组均接受静脉青蒿琥酯治疗。
- 对乙酰氨基酚用法为1g每6小时一次,共72小时。
- 主要结局为72小时后肌酐按中位血浆血红蛋白分层的比例变化。
主要发现
- 对乙酰氨基酚组72小时肌酐中位(四分位距)下降23%(37%至18%),不对乙酰氨基酚组下降14%(29%至0%),P=.043。
- 在血红蛋白≥45000 ng/mL患者中,对乙酰氨基酚组肌酐下降37%(48%至22%),不对乙酰氨基酚组下降14%(30%至-71%),P=.010。
- 对照组进展性肾损伤比例更高(亚分布风险比3.0;95%CI 1.1至8.5;P=.034)。
- 药代动力学-药效学分析显示,对乙酰氨基酚暴露越高,肌酐改善的概率越大。
- 无患者符合Hy's law肝毒性标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury independently predicts mortality in falciparum malaria. It is unknown whether acetaminophen's capacity to inhibit plasma hemoglobin-mediated oxidation is renoprotective in severe malaria. METHODS: This phase 2, open-label, randomized controlled trial conducted at two hospitals in Bangladesh assessed effects on renal function, safety, pharmacokinetic (PK) properties and pharmacodynamic (PD) effects of acetaminophen. Febrile patients (>12 years) with severe falciparum malaria were randomly assigned to receive acetaminophen (1 g 6-hourly for 72 hours) or no acetaminophen, in addition to intravenous artesunate. Primary outcome was the proportional change in creatinine after 72 hours stratified by median plasma hemoglobin. RESULTS: Between 2012 and 2014, 62 patients were randomly assigned to receive acetaminophen (n = 31) or no acetaminophen (n = 31). Median (interquartile range) reduction in creatinine after 72 hours was 23% (37% to 18%) in patients assigned to acetaminophen, versus 14% (29% to 0%) in patients assigned to no acetaminophen (P = .043). This difference in reduction was 37% (48% to 22%) versus 14% (30% to -71%) in patients with hemoglobin ≥45000 ng/mL (P = .010). The proportion with progressing kidney injury was higher among controls (subdistribution hazard ratio, 3.0; 95% confidence interval, 1.1 to 8.5; P = .034). PK-PD analyses showed that higher exposure to acetaminophen increased the probability of creatinine improvement. No patient fulfilled Hy's law for hepatotoxicity. CONCLUSIONS: In this proof-of-principle study, acetaminophen showed renoprotection without evidence of safety concerns in patients with severe falciparum malaria, particularly in those with prominent intravascular hemolysis. CLINICAL TRIALS REGISTRATION: NCT01641289.
引用
- Plewes K, Kingston HWF, Ghose A, et al. Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. Clin Infect Dis. 2018. PMID: 29538635. doi:10.1093/cid/ciy213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。